Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Testing the metabotropic glutamate receptor theory in fragile X syndrome: a randomized, placebo-controlled, proof-of-concept study of AFQ056, a novel, sub-type selective mGluR5 inhibitor

Testing the metabotropic glutamate receptor theory in fragile X syndrome: a randomized, placebo-controlled, proof-of-concept study of AFQ056, a novel, sub-type selective mGluR5 inhibitor. American Society of Human Genetics 2010. 2010.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.